9 April 2026 – United Kingdom
Camstent are delighted to announce a UK multicentre clinical study that has now been published in the journal Antibiotics (MDPI).
The conclusion of the study states the following:
‘Camstent Coated Catheters (CCCs) demonstrated substantially higher infection-free rates than standard care (SC), with 79% versus 46% at Day 7 and 69% versus 39% at Day 14. Notably, within the secondary cohort of long-term catheterized patients, no symptomatic catheter-associated urinary tract infections (CAUTIs) were observed in the CCC group, whereas the incidence was 20% in the standard care (SC) group. In addition, antibiotic use for urinary tract infections was markedly lower among patients receiving CCCs (4.3%) relative to those receiving standard care (21.1%). These findings support the adoption of CCCs as part of strategies to prevent CAUTIs and promote antimicrobial stewardship, particularly in the context of the ongoing limitations of traditional prevention measures such as antibiotic prophylaxis and standard catheter care practices, which have not fully mitigated infection risk. The observed benefits highlight the value and clinical need for novel catheter technologies such as CCC.’
Read the full paper here: https://www.mdpi.com/2079-6382/15/4/369
Camstent will submit the findings from this paper to their Notified Body
